Skip to main content

Table 7 CELsignia analysis of HCC1954 cells using indicated antagonists against a cocktail of agonists (NGR, EGF, HGF)

From: Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy

Drugs

HER/c-met inhibition (%)

Erlotinib (HER1i)

9.2 ± 10.3 (n = 2)

Tepotinib (c-METi)

− 8.8 ± 12.8 (n = 5)

Neratinib (pan-HERi)

14.6 ± 29.6 (n = 4)

Erlotinib + Tepotinib

47.6 ± 0.1 (n = 2)

Neratinib + Tepotinib

82.5 ± 20.1 (n = 4)

  1. Errors listed are in standard deviation
Back to article page

Cell Communication and Signaling

ISSN: 1478-811X